Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Dermatology
•
Primary Care
Do you adjust PSA for finasteride use when determining prostate cancer stage and risk category?
If this upstages the patient, do you modify treatment recommendations?
Answer from: Radiation Oncologist at Community Practice
We generally use the rule of 50% (real PSA is twice the lab value when on Finasteride).
Sign In
or
Register
to read more
7534
Related Questions
Are there any scenarios in which you would offer SBRT as your preferred treatment approach for appropriate candidates with intermediate risk prostate cancer?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
How do you approach radiotherapy planning when there is no identifiable prostate tissue after HIFU or TURP?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
How do you manage prostatic adenocarcinoma after a subtotal resection?